|Day's Range||36.27 - 36.31|
|52 Week Range||33.52 - 38.86|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.63%|
Under the title of "R&D Day", PharmaMar (PHM) hosted an investor meeting in New York to demonstrate its evolution and potential in the areas of R&D. Various members of PharmaMar's management team, together with key global opinion leaders in oncology discussed the company's scientific pipeline. With the aim of defining and contextualizing PharmaMar's research work, the meeting saw the participation of Dr Melinda Telli, an oncologist from the School of Medicine of the University of Stanford, and Dr Martin Forster, an oncologist from the University College of London. Both experts explained their investigative experience and the progress and positive results that have been obtained up to now with lurbinectedin (PM1183), the most advanced molecule in the PharmaMar pipeline, a transcription inhibitor which is directed at treating various cancer including hereditary breast cancer (discussed by Dr Telli) and small cell lung cancer (discussed by Dr Forster) respectively.
MADRID, April 24, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, will host today ...
MADRID, April 6, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, today announced that ...